MedTrace Logo

XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

NCT03399110 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1024

Last updated 2026-01-27

No results posted yet for this study

Summary

Our study aims to compare the efficacy and safety of 4-month versus 6-month adjuvant chemotherapy with capecitabine and oxaliplatin following D2 gastrectomy in patients with gastric cancer.

Hypothesis: In patients with gastric cancer who have undergone D2 gastrectomy, a 4-month regimen of capecitabine and oxaliplatin demonstrates noninferiority to a 6-month regimen in terms of disease-free survival (DFS) and safety.

Conditions

Interventions

DRUG

Oxaliplatin

Oxaliplatin 130 mg/m2

DRUG

Capecitabine

Capecitabine 1000mg/m2

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Dazhi Xu, PHD, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-17
Primary Completion
2026-07-25
Completion
2026-07-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03399110 on ClinicalTrials.gov